ARTICLE | Clinical News

ToleroMune house dust mite therapy: Phase II data

November 22, 2010 8:00 AM UTC

A double-blind, Canadian Phase II trial in 50 patients with house dust mite allergies showed that monthly injections of the optimal dose of ToleroMune T cell vaccine for 3 months reduced early- and la...